Propanc advances assay development for PPC-001 Phase 1b trial in up to 50 cancer patients
PPCB•Propanc Biopharma advanced analytical testing for a planned Phase 1b trial of PPC-001 in up to 50 advanced cancer patients. Previously reported laboratory results showed the drug’s components remained stable in human blood samples.
1. Assay development
Propanc Biopharma said ongoing assay development will support assessment of drug exposure and immune responses in the planned solid-tumor study. Previously reported laboratory results showed PPC-001 components remained stable in human blood samples, supporting clinical sample collection procedures.
